Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.51 |
| ▸ | CDK2 | P24941 | 8/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.48 |
| ▸ | CDK4 | P11802 | 4/20 | 0.48 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701720 | 0.89 | HDAC1 (0.55) | HDAC1CDK2CCNE1CDK4PTGS1 | |
| SCHEMBL699854 | 0.88 | HDAC1 (0.65) | HDAC1CDK2CCNE1CDK4 | |
| SCHEMBL701790 | 0.88 | CDK2 (0.47) | HDAC1CDK2CCNE1CDK4IGF1R | |
| SCHEMBL702866 | 0.87 | HDAC1 (0.52) | HDAC1CDK2CCNE1CDK4IGF1R | |
| SCHEMBL12847223 | 0.86 | CACNA1B (0.41) | HDAC1CDK2PTGS1 | |
| SCHEMBL700586 | 0.86 | HDAC1 (0.61) | HDAC1CDK2CCNE1CDK4IGF1R | |
| SCHEMBL13949015 | 0.84 | HDAC1 (0.45) | HDAC1PTGS1 | |
| SCHEMBL700356 | 0.83 | IGF1R (0.44) | HDAC1CDK2CCNE1CDK4IGF1R | |
| SCHEMBL701827 | 0.82 | HDAC1 (0.51) | HDAC1CDK2CCNE1CDK4IGF1R | |
| SCHEMBL699812 | 0.76 | HDAC1 (0.64) | HDAC1CDK2CCNE1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | claimed |
| JP-2011528040-A | — | — | 2011-11-10 | — | — | JP | claimed |
| EP-2303881-A2 | FUSED HETEROCYCLYC INHIBITORS OF HISTONE DEACETYLASE AND/OR CYCLIN-DEPENDENT KINASES | GILEAD SCIENCES, INC. (US) | 2011-04-06 | — | — | EP | claimed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | claimed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | HDAC1 1/4885CDK2 16/4885CCNE1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.